Market Analysis and Insights: Global Squamous Non-Small Cell Lung Cancer Therapeutics Market
The research report studies the Squamous Non-Small Cell Lung Cancer Therapeutics market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Squamous Non-Small Cell Lung Cancer Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Squamous Non-Small Cell Lung Cancer Therapeutics Scope and Segment
The global Squamous Non-Small Cell Lung Cancer Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Squamous Non-Small Cell Lung Cancer Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
by Application, this report covers the following segments
Research Center
Hospital
Clinic
Global Squamous Non-Small Cell Lung Cancer Therapeutics market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Squamous Non-Small Cell Lung Cancer Therapeutics key players in this market include:
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
The research report studies the Squamous Non-Small Cell Lung Cancer Therapeutics market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Squamous Non-Small Cell Lung Cancer Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Squamous Non-Small Cell Lung Cancer Therapeutics Scope and Segment
The global Squamous Non-Small Cell Lung Cancer Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Squamous Non-Small Cell Lung Cancer Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
by Application, this report covers the following segments
Research Center
Hospital
Clinic
Global Squamous Non-Small Cell Lung Cancer Therapeutics market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Squamous Non-Small Cell Lung Cancer Therapeutics key players in this market include:
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
1 Market Overview of Squamous Non-Small Cell Lung Cancer Therapeutics
1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview
1.1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Product Scope
1.1.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Status and Outlook
1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2016-2027)
1.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Region (2016-2021)
1.5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2016-2027)
1.6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2016-2027)
1.6.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2016-2027)
1.6.3 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2016-2027)
1.6.4 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2016-2027)
1.6.5 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2016-2027)
2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview by Type
2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Type (2016-2021)
2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2022-2027)
2.4 BMS-906024
2.5 Buparlisib Hydrochloride
2.6 FP-1039
2.7 Ipilimumab
2.8 JNJ-42756493
2.9 Lenvatinib
2.10 Others
3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview by Application
3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Application (2016-2021)
3.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2022-2027)
3.4 Research Center
3.5 Hospital
3.6 Clinic
4 Squamous Non-Small Cell Lung Cancer Therapeutics Competition Analysis by Players
4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2020)
4.3 Date of Key Players Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
4.4 Global Top Players Squamous Non-Small Cell Lung Cancer Therapeutics Headquarters and Area Served
4.5 Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Ascenta Therapeutics Inc.
5.1.1 Ascenta Therapeutics Inc. Profile
5.1.2 Ascenta Therapeutics Inc. Main Business
5.1.3 Ascenta Therapeutics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.1.4 Ascenta Therapeutics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.1.5 Ascenta Therapeutics Inc. Recent Developments
5.2 AstraZeneca Plc
5.2.1 AstraZeneca Plc Profile
5.2.2 AstraZeneca Plc Main Business
5.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.2.4 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.2.5 AstraZeneca Plc Recent Developments
5.3 AVEO Pharmaceuticals Inc.
5.3.1 AVEO Pharmaceuticals Inc. Profile
5.3.2 AVEO Pharmaceuticals Inc. Main Business
5.3.3 AVEO Pharmaceuticals Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.3.4 AVEO Pharmaceuticals Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.3.5 Bayer AG Recent Developments
5.4 Bayer AG
5.4.1 Bayer AG Profile
5.4.2 Bayer AG Main Business
5.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.4.4 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.4.5 Bayer AG Recent Developments
5.5 BIND Therapeutics Inc.
5.5.1 BIND Therapeutics Inc. Profile
5.5.2 BIND Therapeutics Inc. Main Business
5.5.3 BIND Therapeutics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.5.4 BIND Therapeutics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.5.5 BIND Therapeutics Inc. Recent Developments
5.6 Boehringer Ingelheim GmbH
5.6.1 Boehringer Ingelheim GmbH Profile
5.6.2 Boehringer Ingelheim GmbH Main Business
5.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.6.4 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.6.5 Boehringer Ingelheim GmbH Recent Developments
5.7 Bristol-Myers Squibb Company
5.7.1 Bristol-Myers Squibb Company Profile
5.7.2 Bristol-Myers Squibb Company Main Business
5.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.7.4 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.7.5 Bristol-Myers Squibb Company Recent Developments
5.8 Eli Lilly and Company
5.8.1 Eli Lilly and Company Profile
5.8.2 Eli Lilly and Company Main Business
5.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.8.4 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.8.5 Eli Lilly and Company Recent Developments
5.9 F. Hoffmann-La Roche Ltd.
5.9.1 F. Hoffmann-La Roche Ltd. Profile
5.9.2 F. Hoffmann-La Roche Ltd. Main Business
5.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.9.4 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.9.5 F. Hoffmann-La Roche Ltd. Recent Developments
5.10 Five Prime Therapeutics Inc.
5.10.1 Five Prime Therapeutics Inc. Profile
5.10.2 Five Prime Therapeutics Inc. Main Business
5.10.3 Five Prime Therapeutics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.10.4 Five Prime Therapeutics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.10.5 Five Prime Therapeutics Inc. Recent Developments
5.11 Genentech Inc.
5.11.1 Genentech Inc. Profile
5.11.2 Genentech Inc. Main Business
5.11.3 Genentech Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.11.4 Genentech Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.11.5 Genentech Inc. Recent Developments
5.12 Incyte Corporation
5.12.1 Incyte Corporation Profile
5.12.2 Incyte Corporation Main Business
5.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.12.4 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.12.5 Incyte Corporation Recent Developments
5.13 Johnson & Johnson
5.13.1 Johnson & Johnson Profile
5.13.2 Johnson & Johnson Main Business
5.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.13.4 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.13.5 Johnson & Johnson Recent Developments
5.14 MacroGenics Inc.
5.14.1 MacroGenics Inc. Profile
5.14.2 MacroGenics Inc. Main Business
5.14.3 MacroGenics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.14.4 MacroGenics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.14.5 MacroGenics Inc. Recent Developments
5.15 Novartis AG
5.15.1 Novartis AG Profile
5.15.2 Novartis AG Main Business
5.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.15.4 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.15.5 Novartis AG Recent Developments
5.16 Oncogenex Pharmaceuticals Inc.
5.16.1 Oncogenex Pharmaceuticals Inc. Profile
5.16.2 Oncogenex Pharmaceuticals Inc. Main Business
5.16.3 Oncogenex Pharmaceuticals Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.16.4 Oncogenex Pharmaceuticals Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.16.5 Oncogenex Pharmaceuticals Inc. Recent Developments
5.17 PsiOxus Therapeutics Limited
5.17.1 PsiOxus Therapeutics Limited Profile
5.17.2 PsiOxus Therapeutics Limited Main Business
5.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.17.4 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.17.5 PsiOxus Therapeutics Limited Recent Developments
6 North America
6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Squamous Non-Small Cell Lung Cancer Therapeutics Market Dynamics
11.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industry Trends
11.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
11.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
11.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview
1.1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Product Scope
1.1.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Status and Outlook
1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2016-2027)
1.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Region (2016-2021)
1.5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2016-2027)
1.6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2016-2027)
1.6.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2016-2027)
1.6.3 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2016-2027)
1.6.4 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2016-2027)
1.6.5 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2016-2027)
2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview by Type
2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Type (2016-2021)
2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2022-2027)
2.4 BMS-906024
2.5 Buparlisib Hydrochloride
2.6 FP-1039
2.7 Ipilimumab
2.8 JNJ-42756493
2.9 Lenvatinib
2.10 Others
3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview by Application
3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Application (2016-2021)
3.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2022-2027)
3.4 Research Center
3.5 Hospital
3.6 Clinic
4 Squamous Non-Small Cell Lung Cancer Therapeutics Competition Analysis by Players
4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2020)
4.3 Date of Key Players Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
4.4 Global Top Players Squamous Non-Small Cell Lung Cancer Therapeutics Headquarters and Area Served
4.5 Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Ascenta Therapeutics Inc.
5.1.1 Ascenta Therapeutics Inc. Profile
5.1.2 Ascenta Therapeutics Inc. Main Business
5.1.3 Ascenta Therapeutics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.1.4 Ascenta Therapeutics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.1.5 Ascenta Therapeutics Inc. Recent Developments
5.2 AstraZeneca Plc
5.2.1 AstraZeneca Plc Profile
5.2.2 AstraZeneca Plc Main Business
5.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.2.4 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.2.5 AstraZeneca Plc Recent Developments
5.3 AVEO Pharmaceuticals Inc.
5.3.1 AVEO Pharmaceuticals Inc. Profile
5.3.2 AVEO Pharmaceuticals Inc. Main Business
5.3.3 AVEO Pharmaceuticals Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.3.4 AVEO Pharmaceuticals Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.3.5 Bayer AG Recent Developments
5.4 Bayer AG
5.4.1 Bayer AG Profile
5.4.2 Bayer AG Main Business
5.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.4.4 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.4.5 Bayer AG Recent Developments
5.5 BIND Therapeutics Inc.
5.5.1 BIND Therapeutics Inc. Profile
5.5.2 BIND Therapeutics Inc. Main Business
5.5.3 BIND Therapeutics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.5.4 BIND Therapeutics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.5.5 BIND Therapeutics Inc. Recent Developments
5.6 Boehringer Ingelheim GmbH
5.6.1 Boehringer Ingelheim GmbH Profile
5.6.2 Boehringer Ingelheim GmbH Main Business
5.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.6.4 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.6.5 Boehringer Ingelheim GmbH Recent Developments
5.7 Bristol-Myers Squibb Company
5.7.1 Bristol-Myers Squibb Company Profile
5.7.2 Bristol-Myers Squibb Company Main Business
5.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.7.4 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.7.5 Bristol-Myers Squibb Company Recent Developments
5.8 Eli Lilly and Company
5.8.1 Eli Lilly and Company Profile
5.8.2 Eli Lilly and Company Main Business
5.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.8.4 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.8.5 Eli Lilly and Company Recent Developments
5.9 F. Hoffmann-La Roche Ltd.
5.9.1 F. Hoffmann-La Roche Ltd. Profile
5.9.2 F. Hoffmann-La Roche Ltd. Main Business
5.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.9.4 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.9.5 F. Hoffmann-La Roche Ltd. Recent Developments
5.10 Five Prime Therapeutics Inc.
5.10.1 Five Prime Therapeutics Inc. Profile
5.10.2 Five Prime Therapeutics Inc. Main Business
5.10.3 Five Prime Therapeutics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.10.4 Five Prime Therapeutics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.10.5 Five Prime Therapeutics Inc. Recent Developments
5.11 Genentech Inc.
5.11.1 Genentech Inc. Profile
5.11.2 Genentech Inc. Main Business
5.11.3 Genentech Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.11.4 Genentech Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.11.5 Genentech Inc. Recent Developments
5.12 Incyte Corporation
5.12.1 Incyte Corporation Profile
5.12.2 Incyte Corporation Main Business
5.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.12.4 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.12.5 Incyte Corporation Recent Developments
5.13 Johnson & Johnson
5.13.1 Johnson & Johnson Profile
5.13.2 Johnson & Johnson Main Business
5.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.13.4 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.13.5 Johnson & Johnson Recent Developments
5.14 MacroGenics Inc.
5.14.1 MacroGenics Inc. Profile
5.14.2 MacroGenics Inc. Main Business
5.14.3 MacroGenics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.14.4 MacroGenics Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.14.5 MacroGenics Inc. Recent Developments
5.15 Novartis AG
5.15.1 Novartis AG Profile
5.15.2 Novartis AG Main Business
5.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.15.4 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.15.5 Novartis AG Recent Developments
5.16 Oncogenex Pharmaceuticals Inc.
5.16.1 Oncogenex Pharmaceuticals Inc. Profile
5.16.2 Oncogenex Pharmaceuticals Inc. Main Business
5.16.3 Oncogenex Pharmaceuticals Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.16.4 Oncogenex Pharmaceuticals Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.16.5 Oncogenex Pharmaceuticals Inc. Recent Developments
5.17 PsiOxus Therapeutics Limited
5.17.1 PsiOxus Therapeutics Limited Profile
5.17.2 PsiOxus Therapeutics Limited Main Business
5.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.17.4 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2016-2021)
5.17.5 PsiOxus Therapeutics Limited Recent Developments
6 North America
6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Squamous Non-Small Cell Lung Cancer Therapeutics Market Dynamics
11.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industry Trends
11.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
11.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
11.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
